# Douglas Hansen-Luke

> Douglas Hansen-Luke is a Series B investor at Future Planet Capital backing Medical. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Future Planet Capital](https://shizune.co/investors/profile/future-planet-capital)
- Location: London, United Kingdom
- Total investments: 1
- Last investment: Mar 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dhansenluke/
- X (Twitter): https://twitter.com/DHansenLuke
- Website: https://x.com/DHansenLuke
- Facebook: https://www.facebook.com/DHansenLukeConservatives/

Douglas Hansen-Luke is a Series B investor at Future Planet Capital in London focused on Medical and Therapeutics. Douglas Hansen-Luke - Executive Chairman @ Future Planet Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Barinthus Biotherapeutics | Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, aswell as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable safety profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca. | $168M | Series B | Mar 17, 2021 |  |

1 of 1 investments shown.

## Co-investors
- [Gilead Sciences](https://shizune.co/investors/profile/gilead-sciences) — VC Fund, 1 deal together
- [M&G Investments](https://shizune.co/investors/profile/m-g-investments-2f25) — VC Fund, 1 deal together
- [Monaco Constitutional Reserve Fund](https://shizune.co/investors/profile/monaco-constitutional-reserve-fund) — VC Fund, 1 deal together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-science-enterprises) — VC Fund, 1 deal together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation) — VC Fund, 1 deal together
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 1 deal together

## About Future Planet Capital

VC Fund · London, United Kingdom

Future Planet is an impact-led venture capital firm that invests in technology and life science companies from leading research centres

5 contacts available at Future Planet Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Guy Pengelley | Investment Director | https://shizune.co/investors/profile/guy-pengelley-dbac |
| Douglas Hansen-Luke | founder | https://shizune.co/investors/profile/douglas-hansen-luke |
| Hassan Mahmudul | VC Investor | https://shizune.co/investors/profile/hassan-mahmudul |
| Lyle Pentith | Portfolio Manager | https://shizune.co/investors/profile/ed-phillips-2ce1 |
| Oliver Sexton | Head of Life Science | https://shizune.co/investors/profile/oliver-sexton |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Douglas Hansen-Luke invest in?

Douglas Hansen-Luke invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Douglas Hansen-Luke last invest?

The most recent investment recorded for Douglas Hansen-Luke closed in Mar 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co